SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Recruiting now · Phase 3

Conditions studied: Hemophilia A

In brief

The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.

Key facts

Study ID

NCT04563520

Run by

Emory University

People needed

5

Starts

2026-06-01

Expected to finish

2027-03-01

Last updated by the study team

2026-04-29

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Moderately severe hemophilia A, defined as FVIII level <0.05 IU/mL before development of an inhibitor
• Age ≥6 years of age at time of informed consent
• Documented on 2 occasions a high titer inhibitor (>5 BU/mL) with a 72-hour washout within 2 years of enrollment
• Parent/guardian (Legally Authorized Representative) or the patient has provided written informed consent
• Adequate hematologic function (Hgb >8 g/dL and platelet count >100,000 µL)
• Adequate hepatic function (total bilirubin ≤1.5 x ULN and both AST/ALT ≤3x ULN at screening (excluding known Gilbert's)
• Adequate renal function (≤2.5 x ULN and CrCl ≥30 mL/min)

You may not qualify if…

• Inherited or acquired bleeding disorder other than hemophilia A excluding low VWF (>30% VWF:RCo or VWF:GP1bm)
• Had an active bleed requiring factor therapy at screening
• Previous or current treatment for thromboembolic disease or signs of thromboembolic disease (excluding previously resolved line-associated thrombosis)
• Had a surgical procedure 14 days before screening
• Conditions that may increase the risk of bleeding or thrombosis
• If the patient is treated with rFVIIa or aPCC seven days before screening
• History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
• Had current use of any medication other than emicizumab that could affect the coagulation system.
• Known HIV infection with CD4 count <200 cells/µL within 24 weeks before screening. Testing is not required if <35 years of age.
• Use of systemic immunomodulators at enrollment or planned use during the study
• Participants who are at high risk for TMA (for example, have a previous medical/family history of TMA), in the investigator's judgment
• Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose an additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study

Where it is running

• Children's Healthcare of Atlanta — Atlanta, Georgia, United States (enrolling)
• Emory University Hospital — Atlanta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.